MKMazin Kharabah

Mazin Kharabah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mazin Kharabah has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmed Hussein Al Murdhimah

    Department of Family Medicine, Primary Health Care Center – Al-Dhubbat District, Najran, Kingdom of Saudi Arabia

    1 shared publication
  • Alaa Mohsen

    Faculty of Medicine, Jeddah University, Jeddah, Kingdom of Saudi Arabia

    1 shared publication
  • Ali Alessa

    College of Pharmacy, University of Hafr Al-Batin, Hafr Al-Batin, Kingdom of Saudi Arabia

    1 shared publication
  • Anas Al-Thagfi

    Faculty of Medicine, King Saud bin Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

    1 shared publication
  • Ehab Abdu

    Sana'a University

    1 shared publication
  • Faisal Alanzi

    Faculty of Medicine, Majmmah University, Majmmah, Kingdom of Saudi Arabia

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials

    by Ehab Abdulrahman Ahmed Abdu, Raghad Alghamdi, Alaa Mohsen, Zahra Alabbad, Mazin Kharabah, Anas Al-Thagfi, Mawadah Al-Shabeeb, Faisal Alanzi, Hanan Al-Harthi, Ali Alessa, et al.

    Background: Metabolic dysfunction–associated steatohepatitis (MASH) is a prevalent and progressive liver disease with limited pharmacologic treatment options. Pemvidutide, a GLP-1–glucagon dual receptor agonist, has shown promise in targeting both hepatic steatosis and fibrosis. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of pemvidutide in adults with MASH. Methods: We systematically searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL through December 15, 2025, for randomized controlled trials (RCTs) comparing once-weekly subcutaneous pemvidutide (1.2 mg, 1.8 mg, or 2.4 mg) with placebo in adult MASH patients. Primary outcomes were changes in liver fat content (LFC, % via MRI-PDFF) and Enhanced Liver Fibrosis (ELF) score. Secondary outcomes included body weight, glycemic and lipid parameters, blood pressure, heart rate, and adverse gastrointestinal events. Dose-specific pairwise meta-analyses were performed using a random-effects model. Results: Three RCTs encompassing 370 participants (195 pemvidutide, 175 placebo) were included. Pemvidutide significantly reduced LFC at all doses, with the greatest effect at 1.8 mg (MD = −21.63%, 95% CI: −27.23 to −16.02; p<0.0001). ELF score improvement was significant at 1.2 mg and 1.8 mg doses but not at 2.4 mg. Across all doses, body weight decreased significantly, while HbA1c remained unchanged. Pemvidutide also reduced systolic blood pressure and total cholesterol (1.8 mg and 2.4 mg), with modest HDL reduction at 2.4 mg. Mild-to-moderate gastrointestinal adverse events were observed, with nausea more frequent at 1.8 mg. Conclusions: Pemvidutide is effective in reducing liver fat and improving cardiometabolic parameters in MASH, with a favorable safety profile. Dose-specific effects on fibrosis suggest potential early antifibrotic activity, highlighting its promise as a dual-targeted therapy for MASH. Further long-term studies are warranted to confirm sustained hepatic and metabolic benefits.